# Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Study · id `cardio:ct-nct03399604` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03399604](<https://clinicaltrials.gov/study/NCT03399604>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03399604

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT03399604. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2019-05-06 (actual). Results posted on 2024-07-30.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Started: 2018-01-02 (actual) (ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Primary completion: 2019-05-06 (actual) (ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Completion: 2019-11-25 (actual) (ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Results first posted: 2024-07-30 (ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03399604, source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03399604-2024-07-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
- Acronym: INSPIRE
- Condition: Primary Pulmonary Hypertension
- Intervention (Drug): LIQ861 Inhaled Treprostinil
- Lead sponsor: Liquidia Technologies, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Nuventra, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 5ddb34b90e7a0179ceeeba08d9944a001071f00eac31ffd70c60fc39480c1c30
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
